

Drug shortage of EpiPen and other authorized generics

Background: There is currently a national shortage of brand-name EpiPens® and the authorized generic (AG) versions of EpiPen and Adrenaclick® due to manufacturing delays.

To address the shortage, on June 5, 2019, the FDA extended the expiration dates by four months for specific lots of 0.3 mg EpiPens and AGs set to expire between February 2019 and October 2020. This extension does not apply to EpiPen Jr® (epinephrine injection, USP 0.15 mg) auto-injector or its AG version.

For a list of the affected lots and new expiration dates, visit the [FDA website](#).

What does this mean to me?

Until the shortage is resolved, your patients may need to have their prescriptions filled at a different pharmacy than normal. Some CVS pharmacies may still have the AG of Adrenaclick in stock.

As of April 23, 2019, Impax Pharmaceuticals, the manufacturer of the AG version of Adrenaclick, has their supply on allocation with limited distribution.

As of June 11, 2019, Meridian, a subsidiary of Pfizer that manufactures EpiPen auto-injectors and the AG versions, continues to experience manufacturing challenges. These challenges are expected to result in tighter supplies and greater variability in pharmacy-level access over the coming weeks and will potentially continue through the summer months as seasonal demand increases.

If your patient needs assistance obtaining an AG version of EpiPen from Mylan, direct them to the Mylan Customer Service Center at 1-800-796-9526 (hours are 8 a.m.-7 p.m. Eastern time Monday-Friday). A Customer Service representative will gather information and contact pharmacies close to the member's location to identify nearby pharmacies with the AG version of EpiPen in stock.

If brand-name EpiPen, the AG version of EpiPen or the AG version of Adrenaclick cannot be obtained for an immediate need, Auvi-Q® is available. Auvi-Q is nonpreferred and requires prior authorization (PA). Since network pharmacies are authorized to dispense a three-day supply of eligible outpatient prescription drugs while awaiting a PA decision in an emergency situation, we encourage you to write a prescription and state *three-day emergency fill* on the prescription. Each member is allowed one emergency fill per medication and dosage strength within 30 days. Auvi-Q for therapy should be discontinued and a new prescription for the AG version of EpiPen or Adrenaclick will be needed when the shortage ends.

What if I need assistance?

If you have questions about this communication, contact your local Provider Relations representative or call Provider Services at 1-800-454-3730.